C. Dolman

发表

“Cytokine Storm” in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics

M. Wadhwa, P. Dilger, C. Bird, 2007, The Journal of Immunology.

EU Forum: The CREATE Project: development of certified reference materials for allergenic products and validation of methods for their quantification

R. G. Das, R. Van Ree, S. Vieths, 2008, Allergy.

The Effects of Environmental Influences and Post‐translational Modification on the Biological Activity of Granulocyte Colony‐stimulating Factor

R. Thorpe, A. Mire-Sluis, C. Dolman, 1999 .

A WHO Reference Reagent for lupus (anti-dsDNA) antibodies: international collaborative study to evaluate a candidate preparation

P. Meroni, B. Fox, C. Dolman, 2019, Annals of the rheumatic diseases.

Measurement of urinary retinol-binding protein by enzyme-linked immunosorbent assay, and its application to detection of tubular proteinuria.

C. Dolman, M. Topping, A. Bernard, 1986, Clinical chemistry.

Characterization of complete particles (VSV-G/SIN-GFP) and empty particles (VSV-G/EMPTY) in human immunodeficiency virus type 1-based lentiviral products for gene therapy: potential applications for improvement of product quality and safety.

R. Thorpe, C. Dolman, Yuan Zhao, 2008, Human gene therapy.

Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti‐Rh D activity

R. Thorpe, B. Fox, C. Dolman, 2003, Vox sanguinis.

Anti-A and anti-B activity in batches of different intravenous immunoglobulin products determined using a direct haemagglutination method.

R. Thorpe, B. Fox, C. Dolman, 2005, Biologicals : journal of the International Association of Biological Standardization.

International collaborative study to evaluate a candidate reference preparation to define an appropriate specified limit of anti‐D in intravenous immunoglobulin products

A. Heath, R. Thorpe, B. Fox, 2005, Vox sanguinis.

This information is current as PreClinical Testing of Immunotherapeutics Understanding the Causes to Improve Monoclonal Antibody TGN1412: Better ''Cytokine Storm'' in the Phase I Trial of

M. Wadhwa, R. Thorpe, L. Findlay, 2013 .

An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products.

M. Wadhwa, P. Dilger, C. Bird, 2011, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Measurementof UrinaryRetinol-Binding Proteinby Enzyme-Linked Immunosorbent Assay, and Its Applicationto Detectionof Tubular Proteinuria

C. Dolman, M. Topping, A. Bernard, 1986 .

Neutralizing antibodies to granulocyte–macrophage colony‐stimulating factor, interleukin‐1α and interferon‐α but not other cytokines in human immunoglobulin preparations

R. G. Das, M. Wadhwa, P. Dilger, 2000 .

Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations.

R. G. Das, M. Wadhwa, P. Dilger, 2000, Immunology.

Enhanced efficacy of anti-D immunoglobulin for treating ITP is not explained by higher immunoglobulin polymer content.

R. Thorpe, C. Dolman, S. Thorpe, 2001, Biologicals : journal of the International Association of Biological Standardization.

EU Forum: The CREATE Project: development of certified reference materials for allergenic products and validation of methods for their quantification

R. G. Das, S. Vieths, K. Fötisch, 2008, Allergy.